Navigation Links
Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
Date:4/16/2008

Results presented at American Association for Cancer Research meeting

indicate that technology could improve control in administration of

non-water-soluble drugs to treat cancer and possibly other diseases

PRINCETON, N.J., April 16 /PRNewswire/ -- Celator Pharmaceuticals today reported results on a novel approach designed to deliver drugs that are incapable of dissolving in water (hydrophobic drugs) in nanoparticles to enhance and control drug circulation. These findings allow the company to combine hydrophobic drugs such as paclitaxel with other anti-cancer drugs, based on the company's proprietary CombiPlex technology(TM). The results were presented today in a poster presentation at the American Association for Cancer Research meeting in San Diego.

CombiPlex(TM) is a drug ratio technology platform that represents a new approach which identifies a ratio of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle, and maintains the ratio in patients with the goal of improving clinical outcomes.

To date, Celator has utilized liposomes to deliver synergistic drug combinations to treat cancer. Hydrophobic drugs such as paclitaxel are not amenable to this form of delivery because they detach from liposomes almost immediately after injection. Celator scientists reported that they were able to generate a library of hydrophobic paclitaxel conjugates incorporated into nanoparticles. In preclinical testing, these nanoparticles were shown to circulate in the blood for more than 24 hours, allowing the drug to accumulate selectively in solid tumors where it can then be released and exposed to the tumor cells.

According to the research findings, the ability to optimize paclitaxel conjugates could make it possible for higher drug levels to be maintained in plasma for extended periods, which is associated with superior preclinical antitumor efficacy when compared to drug delivery involving paclitaxel at its maximum tolerated dose. In addition, preclinical studies involving a drug conjugate of paclitaxel and gemcitabine co-formulated into nanoparticles showed that a synergistic ratio of the two drugs circulating in plasma was maintained for more than 24 hours after intravenous injection.

"Historically, we have applied our technology to approved and widely used anti-cancer drugs using liposomes. By expanding our formulation platform to include nanoparticles for hydrophobic drugs, we now have greater flexibility in delivering synergistic drug combinations with widely varying chemical properties, potentially leading to more product opportunities," said Andrew Janoff, Ph.D., CEO of Celator. "Our goal is to substantially improve clinical outcomes offered by current combination drug therapies."

About Celator

Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach that identifies a ratio of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle, and maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in a Phase 1 trial in patients with leukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at http://www.celatorpharma.com.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 ... attention to these four stocks: The Medicines Co. ... Pharmaceuticals Inc. (NASDAQ: PCRX), and Supernus Pharmaceuticals Inc. ... in the Generic Drugs space which is governed ... The key growth drivers for the industry are wholesalers, ...
(Date:3/28/2017)... 2017 RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... Patent Office (JPO) for the composition of matter ... for the treatment or prevention of fibrotic disorders, ... proliferative retinopathy (Japanese Patent #: 6060071).  This patent ...
(Date:3/27/2017)... SINGAPORE , March 27, 2017 ... a digital health and data analytics company, signed ... collaborations for improving healthcare delivery in the region. ... Institute for Global Health Research and Technology (BIGHEART) ... relationship on several topics related to healthcare IT ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon ... this procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss ...
(Date:3/28/2017)... ... March 28, 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay ... post about women’s hair loss. Although hair transplant procedures can be seen as more ... or genetics can be two reasons a woman may see her hair thinning. , ...
(Date:3/28/2017)... ... 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. ... that his parents and teachers had asked of him that he had neglected to do, ... defy the Almighty Creator. There were some who would have felt themselves to be special ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. ... smile makeovers without requiring a referral. Trimble Dental offers a variety of ... dentistry and dental implants. Whether patients have discolored, crooked or missing teeth in ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... to the OSEHRA popHealth Community in 2014. It is the culmination ... the Developer Open Source Project Group. OSEHRA Organizational Member Zato Health co-funded the ...
Breaking Medicine News(10 mins):